Inotrem

Focus: Inotrem is a French biotechnology company specializing in peptide-based therapeutics with a focus on innovative drug development. Limited public data available on current scale and market position.

Infectious Diseases Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Inotrem

AI assessmentNot Hiring

No open roles listed right now. Follow Inotrem to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Additional biopsies and blood samples

Inflammatory Bowel Diseases

N/A

Clinical Trials (1)

NCT06580418Evaluation of an Anti-TREM-1 Treatment on an ex Vivo Human Intestinal Model

N/A

Help build intelligence for Inotrem

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Peptide therapy is a growing modality with differentiated IP potential and fewer competitors than antibodies or small molecules
Paris-based location offers access to strong European biotech talent and potential EU funding/grant opportunities
Early-stage company offers high leverage for individual contributors to shape pipeline and clinical strategy

Watch Out For

No active clinical trials reported (0 Phase 1/2/3 programs) suggests early preclinical stage with extended timeline to catalysts
Zero reported publications and limited public visibility may signal underdeveloped science communication or early development phase
No hiring activity reported (0 active job postings) raises questions about near-term growth or stability

Generated by Claude from Inotrem's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

blood sampling

Covid19

N/A

Clinical Trials (1)

NCT04544891TREM-1 Pathway Activation in COVID-19

N/A

Blood sampling

Radiation Toxicity

N/A

Clinical Trials (1)

NCT04948840Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis

N/A